Influence to type 2 diabetes by SGLT2 inhibitor ; Elucidation of link between kidney and intestine
| Project/Area Number |
16K19548
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Metabolomics
|
|---|
| Research Institution | Kawasaki Medical School |
|---|
Principal Investigator |
|
|---|
| Research Collaborator |
IKEDA Shiori
NOGAMI Yuka
|
|---|
| Project Period (FY) |
2016-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2017: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2016: ¥3,120,000 (Direct Cost: ¥2,400,000、Indirect Cost: ¥720,000)
|
|---|
| Keywords | SGLT2阻害薬 / 腎臓 / 消化管 / インクレチン / 消化管糖輸送 / 糖尿病 |
|---|
| Outline of Final Research Achievements |
Although SGLT2 inhibitor decreases body weight with promotion of urinary glucose excretion, there are cases in which appetite increases after administration. This fact suggests existence of protective mechanism for energy homeostasis maintenance. When SGLT2 inhibitor was administered, we examined whether there is an association between renal and gastrointestinal tract as energy homeostatic mechanism. Diabetes model mice were divided into SGLT2 inhibitor Luseogliflozin (L) group and control (C) group, and the results of gastrointestinal glucose transport ability, glucose transporters gene expression level and oral glucose tolerance test were compared. In L group, expression of glucose transporters, gastrointestinal glucose transport ability were increased, and GIP and GLP-1 secretion were also augmented, suggesting the presence of association between kidney and gastrointestinal tract.
|
Report
(3 results)
Research Products
(2 results)
